Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice-yearly option for the prevention of HIV ...

The findings mean that for those using preexposure prophylaxis with gender-affirming hormone therapy or long-acting hormonal ...

Gilead Sciences (NASDAQ:GILD) traded higher in the morning hours Thursday after announcing that a Phase 3 trial for its experimental therapy lenacapavir succeeded when used as a twice-yearly option to ...

Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack up. It has been almost 30 years since ex-US ...

The federal government may have contributed far more to the development of HIV pre-exposure prophylaxis (PrEP) than previously estimated, researchers reported. While previous estimates said the ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.